DNTH
Dianthus Therapeutics, Inc. /DE/
$99.91
-1.37 (-1.35%)
At close · Jul 15
Market Cap
$5.21B
Shares
54,666,233
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$99.91
Open$100.01
Day$98.10–102.34
52W$18.08–102.37
Avg vol 30d1.3M
Short int9.5M · 17.4% float · 5.5d
Short vol62%
Last earningsJan 12, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 5
Up next
Next earnings call
Nov 15, 2026
Est · unconfirmed
· in 17 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 5, 2026
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 16.7 · calm
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+60%
above
Price vs 50-day avg
+13%
above
RSI (14)
62
neutral
MACD trend
Positive
52-week position
97%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+21%
trailing
6-month return
+108%
trailing
YTD return
+142%
this year
Relative strength
+98%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $88 › 200d $63 — 50d above 200d
Institutional flow
Accumulating
9 of 242 funds reported for Jun 30 · net +285.8K sh shares · +4 new
Insider flow
Distributing
Net -$2.5M over 90 days · 100% sells
Short interest
Rising
17.44% of float · ▲ +36.6% MoM · 5.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
242 holders — near 3-yr high, broad support
Squeeze score
89
high risk · 0–100
Fundamentals
Revenue growth
−67%
Y/Y
EPS growth
−65%
Y/Y
Free cash flow
$-129.4M
Balance sheet
$51.1M
net cash
Quant / Vol
risk profile
Volatility
65%
annualized · 1-yr
Max drawdown
−20%
past year
ATR
5.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+60%
Bullish
Price vs 50-day avg
+13%
Bullish
RSI (14)
62
Neutral
MACD trend
Positive
Bullish
52-week position
97%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $88 › 200d $63 — 50d above 200d
Institutional flow
Accumulating
9 of 242 funds reported for Jun 30 · net +285.8K sh shares · +4 new
Insider flow
Distributing
Net -$2.5M over 90 days · 100% sells
Short interest
Rising
17.44% of float · ▲ +36.6% MoM · 5.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
242 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $18
Now $100 · 97%
52-wk high $102
vs 200-day avg +60%
vs 50-day avg +13%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DNTH
this stock
Dianthus Therapeutics, Inc. /DE/
|
$5.21B | +142.4% | -67.3% | — | 17.4% |
|
ONC
BeOne Medicines Ltd.
|
$458.76B | +2.5% | +22179.2% | 933.6 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.36B | +5.2% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$71.18B | -13.8% | +20.8% | 16.6 | 3.3% |
|
ARGX
Argenx SE
|
$53.68B | +2.6% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DNTH | +1.9% | +21.1% | +108.0% | +2.5% | +142.4% |
| SPY | +1.3% | -0.2% | +10.1% | +1.1% | +10.7% |
| vs SPY | +0.6% | +21.3% | +97.9% | +1.4% | +131.8% |